tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Arbutus Biopharma and Moderna Agree to Delay Patent Trial

Arbutus Biopharma and Moderna Agree to Delay Patent Trial

Meet Your ETF AI Analyst

Arbutus Biopharma (ABUS) has provided an update.

Arbutus Biopharma Corporation, Genevant Sciences, and Moderna, Inc. have agreed to seek a delay in their ongoing patent infringement lawsuit concerning Moderna’s COVID-19 vaccine, MRNA-1273. The request for an extension aims to allow additional time for discovery, potentially postponing the trial start to late September 2025, pending court approval. This legal development could influence the stock performance of the companies involved.

Learn more about ABUS stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1